Ranbaxy Laboratories Limited has signed a collaborative Research agreement in the area of New Drug Discovery research with Avestha Gengraine Technologies Pvt Ltd, to carry out project activity relating to construction of recombinant cell lines required for screening Ranbaxy's drug candidates.

Commenting on the occasion, Dr Patell, Founder and CEO, Avesthagen, said, "Avesthagen's vision has been to promote new drug discovery and support and enable our Indian Pharma companies to reach and address the needs of the global markets. We are glad to partner with Ranbaxy in this endeavor and look forward to a very fruitful relationship."

On the development, Dr. Kasim Mookhtiar, vice president - NDDR, R&D, Ranbaxy, said, "With the rapid growth of new drug discovery research at Ranbaxy, opportunities exist for collaborative work. We are pleased to avail of Avesthagen's quality R&D services in cutting edge technology to augment our capacity so that our current needs can be met in a timely manner."

Avestha Gengraine Technologies Pvt Ltd is one of the leading biotechnology & bioinformatics companies, focusing on the convergence between food, pharma and clinical genomics leading to preventive personalized medicine.